These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30012092)

  • 1. Variability in distribution and use of tuberculosis diagnostic tests in Kenya: a cross-sectional survey.
    Oliwa JN; Maina J; Ayieko P; Gathara D; Kathure IA; Masini E; Van't Hoog AH; van Hensbroek MB; English M
    BMC Infect Dis; 2018 Jul; 18(1):328. PubMed ID: 30012092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
    Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
    Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis.
    Page AL; Ardizzoni E; Lassovsky M; Kirubi B; Bichkova D; Pedrotta A; Lastrucci C; de la Tour R; Bonnet M; Varaine F
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1078-83, i-iii. PubMed ID: 26260829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.
    Naidoo P; Dunbar R; Lombard C; du Toit E; Caldwell J; Detjen A; Squire SB; Enarson DA; Beyers N
    PLoS One; 2016; 11(3):e0150487. PubMed ID: 26930400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1115-24, i-xv. PubMed ID: 26260835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
    Raizada N; Sachdeva KS; Nair SA; Kulsange S; Gupta RS; Thakur R; Parmar M; Gray C; Ramachandran R; Vadera B; Ekka S; Dhawan S; Babre A; Ghedia M; Alavadi U; Dewan P; Khetrapal M; Khanna A; Boehme C; Paramsivan CN
    PLoS One; 2014; 9(8):e105346. PubMed ID: 25140877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing new tuberculosis diagnostics: the impact of Xpert(®) MTB/RIF testing on case notifications in Nepal.
    Creswell J; Rai B; Wali R; Sudrungrot S; Adhikari LM; Pant R; Pyakurel S; Uranw D; Codlin AJ
    Int J Tuberc Lung Dis; 2015 May; 19(5):545-51. PubMed ID: 25868022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution patterns of drug resistance Mycobacterium tuberculosis among HIV negative and positive tuberculosis patients in Western Kenya.
    Ogwang MO; Imbuga M; Ngugi C; Mutharia L; Magoma G; Diero L
    BMC Infect Dis; 2021 Nov; 21(1):1175. PubMed ID: 34809602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.
    Raizada N; Sachdeva KS; Swaminathan S; Kulsange S; Khaparde SD; Nair SA; Khanna A; Chopra KK; Hanif M; Sethi GR; Umadevi KR; Keshav Chander G; Saha B; Shah A; Parmar M; Ghediya M; Jaju J; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(10):e0140375. PubMed ID: 26469691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.